Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alpha-synuclein and Parkinson's disease.

C B Lücking1, A Brice

  • 1H pital de la Salpetrière, INSERM U 289, Paris, France.

Cellular and Molecular Life Sciences : CMLS
|February 24, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic variation and pesticide exposure influence blood DNA methylation signatures in females with early-stage Parkinson's disease.

NPJ Parkinson's disease·2024
Same author

The PINK1 kinase-driven ubiquitin ligase Parkin promotes mitochondrial protein import through the presequence pathway in living cells.

Scientific reports·2019
Same author

The genetic landscape of Parkinson's disease.

Revue neurologique·2018
Same author

Comparing ataxias with oculomotor apraxia: a multimodal study of AOA1, AOA2 and AT focusing on video-oculography and alpha-fetoprotein.

Scientific reports·2017
Same author

The Autosomal Recessive Form of CMT Disease Linked to 5q31-q33.

Annals of the New York Academy of Sciences·2017
Same author

The Autosomal Recessive Form of CMT Disease Linked to 5q31-q33.

Annals of the New York Academy of Sciences·2017

Alpha-synuclein aggregation is implicated in neurodegenerative diseases like Parkinson's disease. Preventing its pathological aggregation offers a potential therapeutic strategy for these conditions.

Area of Science:

  • Neurobiology
  • Molecular Biology
  • Neurodegenerative Diseases

Background:

  • Alpha-synuclein's role in neurodegeneration was initially suspected due to its presence in Alzheimer's disease amyloid plaques.
  • Mutations in alpha-synuclein are linked to autosomal-dominant Parkinson's disease.
  • Alpha-synuclein is a key component of Lewy bodies and Lewy neurites, the pathological hallmarks of Parkinson's disease.

Purpose of the Study:

  • To explore the role of alpha-synuclein in neurodegenerative disease pathogenesis.
  • To investigate the potential toxicity of alpha-synuclein oligomers.
  • To identify therapeutic strategies targeting alpha-synuclein aggregation.

Main Methods:

  • Isolation of alpha-synuclein fragments from amyloid plaques.

Related Experiment Videos

  • Genetic analysis of alpha-synuclein mutations in familial Parkinson's disease.
  • Biochemical characterization of alpha-synuclein aggregation in vitro.
  • Investigation of alpha-synuclein interactions with cellular components.

    • Main Results:

    • Alpha-synuclein aggregation is strongly associated with Parkinson's disease pathogenesis.
    • Soluble alpha-synuclein oligomers may be more neurotoxic than insoluble fibrils.
    • Various factors can accelerate alpha-synuclein aggregation in vitro.
    • Alpha-synuclein interacts with proteins and phospholipids, suggesting roles in signaling pathways.

    Conclusions:

    • Alpha-synuclein aggregation is a critical factor in neurodegeneration, particularly in Parkinson's disease.
    • Targeting alpha-synuclein aggregation represents a promising therapeutic avenue.
    • Disruption of alpha-synuclein's normal function may also contribute to disease pathology.